Drugs / PRGN-3007
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05694364 | Jan 2023 → Apr 2024 | chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, triple-negative breast carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRGN-3007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05694364 ↗ |
| Modality | Cell therapy | “PRGN-3007 T cells are autologous T cells that are genetically modified ex vivo” NCT05694364 ↗ |
| Target | ROR1 | “express a ROR1-specific chimeric antigen receptor (ROR1 CAR)” NCT05694364 ↗ |